{"id":29580,"date":"2022-02-15T13:20:14","date_gmt":"2022-02-15T12:20:14","guid":{"rendered":"https:\/\/www.satt.fr\/?p=29580"},"modified":"2022-02-16T09:17:55","modified_gmt":"2022-02-16T08:17:55","slug":"new-biomarker-for-diagnosing-triple-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/","title":{"rendered":"Erganeo : New biomarker for diagnosing triple negative breast cancer."},"content":{"rendered":"<p><b><i><span lang=\"EN-GB\">Joint efforts between CliniSciences, Erganeo and the academic lab headed by V\u00e9ronique Baud, in the field of research to facilitate the diagnosis of triple negative breast cancer have yielded new findings that make it easier to classify and predict degree of aggressiveness.<\/span><\/i><\/b><\/p>\n<p><span lang=\"EN-GB\">Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases and primarily affects women under the age of 40. This type of breast cancer is considered highly aggressive with a five-year survival rate of 11.3%. Furthermore, because of its diversity, its degree of aggressiveness is difficult to classify and predict.<\/span><\/p>\n<p><span lang=\"EN-GB\">To tackle these challenges in classifying degree of aggressiveness in TNBC, INSERM Research Director V\u00e9ronique Baud, heading up a laboratory at the Universit\u00e9 de Paris Faculty of Pharmacy, developed an antibody that can be used as a research tool for classifying breast cancers, and aggressive breast cancers in particular.\u00a0<\/span><\/p>\n<p><span style=\"font-family: georgia, palatino, serif;\"><a class=\"file file--mime-application-pdf file--application-pdf\" href=\"https:\/\/www.erganeo.com\/sites\/default\/files\/inline-files\/2022_02_15_CP%20Clinisciences_ENG.pdf\" target=\"_blank\" rel=\"noopener\" data-entity-type=\"file\" data-entity-uuid=\"d5815dbc-faea-44d3-a030-d57ff70b6d4d\">Read the press release<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Joint efforts between CliniSciences, Erganeo and the academic lab headed by V\u00e9ronique Baud, in the field of research to facilitate the diagnosis of triple negative breast cancer have yielded new findings that make it easier to classify and predict degree of aggressiveness. Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":29565,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567],"tags":[],"class_list":["post-29580","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Erganeo : New biomarker for diagnosing triple negative breast cancer. - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline PONTIFICE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/\"},\"author\":{\"name\":\"Caroline PONTIFICE\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/64ee65998b5d45d20e9cfd11af51d410\"},\"headline\":\"Erganeo : New biomarker for diagnosing triple negative breast cancer.\",\"datePublished\":\"2022-02-15T12:20:14+00:00\",\"dateModified\":\"2022-02-16T08:17:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/\"},\"wordCount\":156,\"image\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Image-cancer-du-sein.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/\",\"name\":\"Erganeo : New biomarker for diagnosing triple negative breast cancer. - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Image-cancer-du-sein.png\",\"datePublished\":\"2022-02-15T12:20:14+00:00\",\"dateModified\":\"2022-02-16T08:17:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/64ee65998b5d45d20e9cfd11af51d410\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Image-cancer-du-sein.png\",\"contentUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Image-cancer-du-sein.png\",\"width\":944,\"height\":528},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Erganeo : New biomarker for diagnosing triple negative breast cancer.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/64ee65998b5d45d20e9cfd11af51d410\",\"name\":\"Caroline PONTIFICE\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/author\\\/caroline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Erganeo : New biomarker for diagnosing triple negative breast cancer. - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/","twitter_misc":{"Written by":"Caroline PONTIFICE","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/"},"author":{"name":"Caroline PONTIFICE","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/64ee65998b5d45d20e9cfd11af51d410"},"headline":"Erganeo : New biomarker for diagnosing triple negative breast cancer.","datePublished":"2022-02-15T12:20:14+00:00","dateModified":"2022-02-16T08:17:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/"},"wordCount":156,"image":{"@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2022\/02\/Image-cancer-du-sein.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/","url":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/","name":"Erganeo : New biomarker for diagnosing triple negative breast cancer. - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2022\/02\/Image-cancer-du-sein.png","datePublished":"2022-02-15T12:20:14+00:00","dateModified":"2022-02-16T08:17:55+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/64ee65998b5d45d20e9cfd11af51d410"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2022\/02\/Image-cancer-du-sein.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2022\/02\/Image-cancer-du-sein.png","width":944,"height":528},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/new-biomarker-for-diagnosing-triple-negative-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Erganeo : New biomarker for diagnosing triple negative breast cancer."}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/64ee65998b5d45d20e9cfd11af51d410","name":"Caroline PONTIFICE","url":"https:\/\/www.satt.fr\/en\/author\/caroline\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/29580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=29580"}],"version-history":[{"count":5,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/29580\/revisions"}],"predecessor-version":[{"id":29597,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/29580\/revisions\/29597"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/29565"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=29580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=29580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=29580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}